The role of automated insulin delivery technology in diabetes
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
The role of automated insulin delivery systems in diabetes is expanding. Hybrid closed-loop systems are being used in routine clinical practice for treating people with type 1 diabetes. Encouragingly, real-world data reflects the performance and usability observed in clinical trials. We review the commercially available hybrid closed-loop systems, their distinctive features and the associated real-world data. We also consider emerging indications for closed-loop systems, including the treatment of type 2 diabetes where variability of day-to-day insulin requirements is high, and other challenging applications for this technology. We discuss issues around access and implementation of closed-loop technology, and consider the limitations of present closed-loop systems, as well as innovative approaches that are being evaluated to improve their performance. Graphical Abstract
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Variability of day-to-day insulin requirements as determined by closed-loop insulin delivery across different populations with diabetes. Data presented are mean with SD. Samples size: type 1 diabetes age 1–6 years n=20, 7–12 years n=21, 13–17 years n=18, adults n=58; type 2 diabetes outpatients n=25, inpatients n=67 (data from references [43, 44, 65]). IP, inpatients; OP, outpatients; T1D, type 1 diabetes, T2D, type 2 diabetes; y, years. This figure is available as part of a downloadable slideset](https://figures.cochat.ai/paper-figures/09c6de5336f046bfa7a7e934f56bade0/the-role-of-automated-insulin-delivery-technology-in-diabetes-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The greatest improvements were seen with AID when used in individuals with the highest baseline A1C or lowest TIR (220).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [220]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030 · cited 1×
“…Control-IQ hybrid closed-loop algorithm, hosted on the t:slim X2 insulin pump (Tandem, CA, USA), uses pre-programmed basal rates, correction factors and carbohydrate-to-insulin ratios as part of its algorithm inputs, while the correction target and active insulin time are fixed in the system [28].”
MethodFeig, D. S., Donovan, L. E., Corcoy, R., Murphy, K. E., Amiel, S. A., Hunt, K. F., Asztalos, E., Barrett, J. F. R., Sanchez, J. J., de Leiva, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32400-5 · Cited by 803
Phillip, M., Nimri, R., Bergenstal, R. M., Barnard-Kelly, K., Danne, T., Hovorka, R., Kovatchev, B. P., Messer, L. H., Parkin, C. G., Ambler-Osborn, L., et al. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac022 · Cited by 443
Self-citationBekiari, E., Kitsios, K., Thabit, H., Tauschmann, M., Athanasiadou, E., Karagiannis, T., Haidich, A.-B., Hovorka, R., & Tsapas, A. (2018) · BMJ · doi:10.1136/bmj.k1310 · Cited by 437
Self-citationMurphy, H. R., Howgate, C., O'Keefe, J., Myers, J., Morgan, M., Coleman, M. A., Jolly, M., Valabhji, J., Scott, E. M., Knighton, P., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30406-x · Cited by 346 · cited 1×
“Pregnant women with diabetes Attaining recommended tight glucose control during pregnancy is particularly difficult due to marked gestational variations in insulin sensitivity and altered eating patterns [45].”
BackgroundBergenstal, R. M., Nimri, R., Beck, R. W., Criego, A., Laffel, L., Schatz, D., Battelino, T., Danne, T., Weinzimer, S. A., Sibayan, J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32514-9 · Cited by 344 · cited 1×
“…CA, USA) has been super-seded by the second generation MiniMed 780G, which has improved usability (fewer auto mode exits and alarms) and improved glucose management with automated bolus insulin corrections and a meal detection module in addition to the existing features of the MiniMed 670G [27].”
BackgroundOne Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology
Breton, M. D., & Kovatchev, B. P. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0097 · Cited by 250 · cited 1×
“Real-world usability has been reported in a smaller dataset (>9000 users) where time spent in closed-loop mode was 94% [36].”
BackgroundAutomated insulin delivery in women with pregnancy complicated by type 1 diabetes
Lee, T. T. M., Collett, C., Bergford, S., Hartnell, S., Scott, E. M., Lindsay, R. S., Hunt, K. F., McCance, D. R., Barnard-Kelly, K., Rankin, D., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303911 · Cited by 241
Self-citationClosed-loop insulin delivery for glycemic control in noncritical care
Bally, L., Thabit, H., Hartnell, S., Andereggen, E., Ruan, Y., Wilinska, M. E., Evans, M. L., Wertli, M. M., Coll, A. P., Stettler, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805233 · Cited by 232 · cited 1×
“The same fully automated closed-loop system has also shown safety and efficacy in inpatients during acute hospital admissions [14, 15].”
BackgroundSelf-citationBenhamou, P.-Y., Franc, S., Reznik, Y., Thivolet, C., Schaepelynck, P., Renard, E., Guerci, B., Chaillous, L., Lukas-Croisier, C., Jeandidier, N., et al. (2019) · The Lancet Digital Health · doi:10.1016/s2589-7500(19)30003-2 · Cited by 217 · cited 1×
“DBLG1 allows users to customise the algorithm through ten different settings including target glucose level and hypoglycaemia threshold [29].”
Background
Research works printed but not linked: 2
- International Diabetes Federation (2019) IDF Diabetes Atlas 9th Edition 2019. Available from https://diabetesatlas.org/idfawp/resource-files/2019/07/IDF_diabetes_atlas_ninth_edition_en.pdf
- National Institute for Health and Care Excellence (2023) Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes. Technology appraisal guidance. TA943. Available from https://www.nice.org.uk/guidance/ta943, published 19 Dec 2023 40245209
Cited by
7. Diabetes Technology: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s007 · Cited by 348
7. Diabetes Technology: Standards of Care in Diabetes—2026
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s007 · Cited by 288
Wang, X., Si, J., Li, Y., Tse, P., Zhang, G., Wang, X., Ren, J., Xu, J., Sun, J., & Yao, X. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01819-0 · Cited by 33
“This intelligent regulation helps mitigate the risks of hyperglycemia and hypoglycemia, thereby improving overall glycemic management [29, 31, 37–39].”
Towards Personalized AI-Based Diabetes Therapy: A Review
Campanella, S., Paragliola, G., Cherubini, V., Pierleoni, P., & Palma, L. (2024) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2024.3443137 · Cited by 38
“Nowadays, a person with diabetes can also receive decision support from a medical professional who makes recommendations via a mobile interface, or directly from the patient using a smartphone app that generates recommendations on its own [8], [9], [10].”
BackgroundDe Meulemeester, J., Keymeulen, B., De Block, C., Van Huffel, L., Taes, Y., Ballaux, D., Spincemaille, K., Lapauw, B., Vanhaverbeke, G., Lowyck, I., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06366-x · Cited by 27
“The superiority of HCL systems compared with other intensive insulin regimens in improving glucose management, minimising hypoglycaemia and enhancing quality of life for people with type 1 diabetes from all ages has been established in numerous RCTs [1–12].”
Closed-loop systems: recent advancements and lived experiences
Kadiyala, N., Hovorka, R., & Boughton, C. K. (2024) · Expert Review of Medical Devices · doi:10.1080/17434440.2024.2406901 · Cited by 33
“There are no in-depth reports of the psychosocial impact or cost-efficacy of CLS in T2D and people with CFRD and this warrants further research [72].”
BackgroundInfluentialSelf-citationPöhlmann, J., Smith‐Palmer, J., Serné, E. H., Tuomaala, A., JENDLE, J. H., Choudhary, P., Bosi, E., Mohan, V., van den Heuvel, T. R. A., Cohen, O., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70161 · Cited by 23
“2 Published guidance recommends AID for insulin delivery in paediatric and adult populations with T1D, 34,42,108 particularly in people not achieving individual treatment targets on intensified insulin therapy using CGM or suffering from frequent or severe hypoglycaemia.”
Materials and System Design for Self‐Decision Bioelectronic Systems
Zeng, Q., Liu, H., Zhang, Y., Zheng, Y., Ding, X., Zhu, M., Shi, G., Wang, Y., Haick, H., & Zhang, M. (2026) · Advanced Materials · doi:10.1002/adma.202521164 · Cited by 33
The future is here: an overview of technology in diabetes
Mallik, R., Kar, P. S., Mulder, H., & Krook, A. (2024) · Diabetologia · doi:10.1007/s00125-024-06235-z · Cited by 23
“In addition, there is emerging evidence for the use of closed-loop systems in people with CFRD [12].”
InfluentialDigital health technologies and innovation patterns in diabetes ecosystems
Giger, O.-F., Pfitzer, E., Mekniran, W., Gebhardt, H., Fleisch, E., Jovanova, M., & Kowatsch, T. (2025) · DIGITAL HEALTH · doi:10.1177/20552076241311740 · Cited by 19
Ying, Z., Li, X., & Chen, Y. (2025) · Journal of Translational Internal Medicine · doi:10.1515/jtim-2025-0039 · Cited by 12
AI-Driven Management of Type 2 Diabetes in China: Opportunities and Challenges
He, Z., & Li, W. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s495364 · Cited by 13
“Recent studies 16,17 have shown that automated insulin delivery (AID) plays an increasingly important role in diabetes management.”
Mo, Y., Zhao, F., Yuan, L., Xing, Q., Zhou, Y., Wu, Q., Li, C., Lin, J., Wu, H., Deng, S., et al. (2025) · International Journal of Nursing Sciences · doi:10.1016/j.ijnss.2025.04.013 · Cited by 15
“AID systems combine continuous glucose monitoring (CGM) with smart insulin pumps to automate insulin delivery, improve glycemic control, and enhance the quality of life [8,9].”
Data Visualisation Models for Analytics Use Artificial Intelligence to Predict Diabetes in Women
Almngoshi, H. Z., Mithra, C., Ratnam, A. S. K., Shanmugam, S., Saravanan, V., & Marapelli, B. (2025) · Journal of Machine and Computing · doi:10.53759/7669/jmc202505043 · Cited by 9
Closed-loop therapy: recent advancements and potential predictors of glycemic outcomes
Royston, C., Hovorka, R., & Boughton, C. K. (2025) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2025.2492363 · Cited by 12
“One system (the iLet) does not require carbohydrate counting but still requires meal announcements [3, 5].”
Self-citationAutomated Insulin Delivery for Type 1 Diabetes: Present and Future
Akcan, T., Lee, M. Y., Needleman, L., & Lal, R. (2025) · Diabetes Spectrum · doi:10.2337/dsi25-0003 · Cited by 6
Hussain, S., Saltik, A. Z. O., Yu, J. J., de Portu, S., Pollock, R. F., Pöhlmann, J., & Cohen, O. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251380593 · Cited by 8
Is Omnipod 5 cost effective for the management of type 1 diabetes among adults in France?
Riveline, J., Hopley, C. D. J., Olivieri, A., Guigand, G., Littlewood, M., & Penfornis, A. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101721 · Cited by 6
Picard, S., Courbebaisse, B., Dupont, J., Amiot-Chapoutot, F., Lecornet‐Sokol, E., Personeni, E., Mougel, F., Bouché, C., Giroud, F., Lablanche, S., et al. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101617 · Cited by 7
Papa, G. F. S., Cannarella, R., Gusmano, C., Finocchiaro, C., Anzaldi, M., Gruttadauria, G., Patti, L., Presti, D. L., Calabrisotto, S. S., Condorelli, R. A., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112476 · Cited by 5
The Transformative Role of Artificial Intelligence in Diabetes Care and Research.
Canha, D., Bour, C., Barraud, S., Aguayo, G., & Fagherazzi, G. (2024) · Diabetes & Metabolism · doi:10.1016/j.diabet.2024.101565 · Cited by 4
Real-Time Medical IoT for Continuous Glucose Monitoring
Goel, A., Tamrakar, P., Lal, M., Bhende, M. S., Wani, M., & Saoji, S. (2024) · International Conference on Intelligent Systems and Advanced Applications (ICISAA) · doi:10.1109/icisaa62385.2024.10828888 · Cited by 2
System architecture control design and clinical translation in closed-loop drug delivery
Qin, W., Cui, Y., Wang, H., Zhang, Y., & Cheng, Z. (2026) · Materials Today Chemistry · doi:10.1016/j.mtchem.2026.103601 · Cited by 2
Onetto, M. T., Montt‐Blanchard, D., Berget, C., Strodhoff, K., & Grassi, B. A. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70034 · Cited by 3
Early Stages of Automated Insulin Delivery
Zisser, H., Hovorka, R., Basu, A., Battelino, T., Boughton, C. K., Breton, M. D., Buckingham, B. A., Brown, S. A., Cherñavvsky, D. R., Dassau, E., et al. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.18802.hz · Cited by 3
Self-citationKourounis, G., Tingle, S. J., Maillo-Nieto, A., Wroe, C., Thompson, E. R., Owen, R. V., van Leeuwen, L. L., Holzner, M. L., Wadhera, V., Akhtar, M. Z., et al. (2025) · Transplant International · doi:10.3389/ti.2025.14940 · Cited by 1
“…insulin pump and continuous glucose monitoring systems, cannot restore optimal glycemic control with unavoidable continued exposure to low glucose levels and unremitting daily self-management burden, making β -replacement therapies the treatment of choice to restore long-term normoglycemia [4, 5].”
Glucose data interpretation in pediatric diabetes using an artificial intelligence approach
Paragliola, G., Campanella, S., Cherubini, V., Tiberi, V., Pierleoni, P., Belli, A., Iannilli, A., & Palma, L. (2025) · Smart Health · doi:10.1016/j.smhl.2025.100616 · Cited by 1
Jeandidier, N., Bagel, A., Bonin, A., Guigand, G., & Guerci, B. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01814-8 · Cited by 1
“…pumps with continuous glucose monitoring (CGM) and algorithm-based insulin adjustments—have been shown to improve glycemic control, reduce time spent in hypo-and hyperglycemia, and enhance quality of life for people with type 1 diabetes (T1D) and insulin-requiring type 2 diabetes (T2D) [5–8].”
Koning, S. J., Dekker, P., Birnie, E., van den Heuvel, T. R. A., Castañeda, J., van Beers, K. A. J., Veeze, H. J., Cohen, O., & Aanstoot, H. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70410 · Cited by 1
Cutting-edge nanotechnology in diabetes care: metamorphosing diagnostics and treatment strategies
Sarkhel, S., Shuvo, S. M., Sarkar, T., GHOSH, A., Kapat, P., & Biswas, R. (2026) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-026-00941-8 · Cited by 3
DeSalvo, D. J., Linde, N. M., Sickler, J. K., Villegas, C., & Cescon, M. (2026) · Journal of Diabetes Research · doi:10.1155/jdr/2896084 · Cited by 1
Sodeify, R., Seyednazari, M. A., Dorosti, A. M., & Nourazarian, A. (2026) · Journal of Materials Science Materials in Medicine · doi:10.1007/s10856-026-07070-x · Cited by 3
“These factors are critical for closed-loop insulin delivery systems [387, 388].”
Ayhan, D. B., & Özdemir, S. (2026) · Journal of Pediatric Nursing · doi:10.1016/j.pedn.2026.08.011 · Cited by 1
Early Stages of Automated Insulin Delivery
Zisser, H., Hovorka, R., Basu, A., Battelino, T., Boughton, C. K., Breton, M. D., Buckingham, B. A., Brown, S. A., Cherñavvsky, D. R., Dassau, E., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251335685 · Cited by 2
Self-citationNolte, J., & Müssig, K. (2025) · Die Diabetologie · doi:10.1007/s11428-025-01365-3
Insulin pumps and artificial pancreas
Markakis, K. P., & Vazeou, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00296-x
Al-Taie, A., Hafida, M., Abdulsattar, M., & Mahmoud, R. E. (2026) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-026-00597-z · Cited by 1
“Recent studies also reported that automated insulin administration (AID) is becoming more crucial in the treatment of diabetes [52, 53].”
Rozario, N. M., & Shanthi, M. (2025) · IEEE International Conference on Innovations in Engineering and Next-Generation Technologies for Sustainability (ICINVENTS) · doi:10.1109/icinvents64613.2025.11401409
“The integration of continuous glucose monitoring (CGM) with automated insulin delivery systems has revolutionized diabetes care [5,6].”
Ritz, P.-J., Aguayo, G., Cosson, E., Canha, D., Renard, É., Merwin, R. M., Amouyal, C., Arnault, G., Bilariki, K., Borot, S., et al. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-104542 · Cited by 1
Editorial: Uncommon or rare forms of diabetes: from diagnosis to management
Grancini, V., & Bolla, A. M. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1831564
“Clinicians must look beyond the traditional dichotomy of “type 1 or type 2” and maintain a high index of suspicion for alternative diagnoses (7); this will enable early genetic and molecular characterization, integration of novel interventions, and application of advanced technologies (9, 11).”
Succurro, E., Cersosimo, G., Sarnelli, P., Brisinda, F. M., Gattuso, I., Mazza, V., Fabiano, G., Iorio, F., Arena, R., Mazzitello, G., et al. (2026) · Acta Diabetologica · doi:10.1007/s00592-026-02690-9
“…from trial data show that AID systems outperform non-automated systems with improvements in time spent in the target glucose range of approximately 8–12% points, reduced time spent in hyperglycaemia, reduced mean glucose and either a reduction or no increase in time in hypoglycaemia [3, 7].”
InfluentialCalles, A. L., Chaparro, P. P., & Fernández, J. M. (2026) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2026.501820
Jurado, A. L., García-Ruiz, A., Guerrero‐del‐Cueto, F., Gómez‐Perea, A., Gutiérrez, S. G., Fuentes-Lupiáñez, C., Torre, C. L.-D. L., & Gea, I. L. (2026) · Endocrines · doi:10.3390/endocrines7020029
Precision Insulin-Pump Calibration and Optimal Insulin Delivery to Improve Blood Glucose LevelsPreprint
Aganj, I., Bryant, N. K., Panaro, L. (., Caravan, P. D., Gaglia, J. L., & Fischl, B. R. (2026) · medRxiv · doi:10.64898/2026.07.27.26359073
Volčanšek, Š., Vidmar, P., Janež, A., & Skvarča, A. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1910192
“Similarly, hybrid closed-loop therapy has been shown to reduce TBR without compromising glycaemic control in adults with T1D, even when compared with optimized manual therapy (33).”
Ratan, P., Abreu, M., Saldarriaga, L., Faria, H. S., & Trevisan, T. L. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113492
Emerging therapies expected to make a difference in Parkinson's disease management
An, Y. A., & Kalia, L. V. (2026) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2026.108962
Holt, R. I. G., DeVries, J. H., Fischl, A. H., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, É., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06833-z · Cited by 1
Vers une diabétologie augmentée par l’IA : état des lieux et perspectives
Fagherazzi, G. (2026) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(25)48886-6
Martínez-Martínez, H., Alfonso, J. M., Sánchez-Rojo-Huertas, B., Visier‐Alfonso, M. E., Sebastián‐Valles, F., Díez‐Fernández, A., Perez-Moreno, A., & Martínez‐Vizcaíno, V. (2026) · Journal of Medical Internet Research · doi:10.2196/105329 · Cited by 1
“AI-driven technologies, particularly machine learning (ML) algorithms, now support advanced tools such as hybrid closed-loop systems, which automate insulin delivery in response to real-time glucose sensor data [10,11].”
Insulin pens and the digital ecosystem
JENDLE, J. H., Adolfsson, P., Cardona‐Hernandez, R., Crenier, L., Molfetta, S. D., Ehrmann, D., Giorgino, F., Haluzík, M., Hirsch, I. B., Irace, C., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06858-4 · Cited by 1
“Healthcare disparities and inequalities, barriers to reimbursement and barriers to access considerably limit the widespread use of AID systems [4, 25–27].”
Three-Year Real-World Performance of Bihormonal Fully Closed-Loop Therapy in Type 1 Diabetes
Jansen, T. J. P., den Drijver, C., Vlaskamp, L. B., & van Bon, A. C. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261492793
Jancev, M., Snoek, F. J., van der Meulen, M. P., Knottnerus, H., Vlaskamp, L. B., Witkop, M., Moons, K. G. M., de Valk, H. W., van Bon, A. C., DeVries, J. H., et al. (2026) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2026.101872
Le, J., Li, X.-X., & Qin, S.-L. (2026) · Digital Health · doi:10.1177/20552076261494727
Naik, V. V., Manzoni, E., Escorihuela‐Altaba, C., & Garcia‐Tirado, J. (2026) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2026.109658
Tumminia, A., Papa, G., Cannarella, R., Galeano, F., Oteri, V., Amato, V., Baratta, R., Condorelli, R. A., Palazzolo, R., Gusmano, C., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113613
Mulder, H. (2026) · Diabetologia · doi:10.1007/s00125-026-06889-x
“Glucose sensors and connected insulin pumps are rapidly improving, meaning that the introduction of truly closed loop systems, a mechanical endocrine pancreas if you will, is imminent [4].”
Metadata
- Authors
- Boughton, C. K., & Hovorka, R.
- Affiliations
- University of Cambridge (GB)
- Corresponding author
- Boughton, Charlotte K.
- Venue
- Diabetologia
- Published
- 2024-05-13
- Volume
- 67
- Issue
- 10
- Pages
- 2034-2044
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC11457686
- OpenAlex
- W4396850881
- Cited by
- 57
- References
- 62
- Citations by year
- 2026: 26 · 2025: 25 · 2024: 6
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Diabetologia (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Apollo (cc-by)
- Funders
- National Institute for Health and Care Research (14/23/09)
- Department of Health and Social Care
- NIHR Cambridge Biomedical Research Centre
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- artificial pancreas, hybrid closed-loop system, type 1 diabetes, type 2 diabetes, insulin pump therapy, real-world data
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Insulin, Insulin Infusion Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.